Alzheimer’s Disease Validation for NeuroVo... | 17-Aug-2022 | 07:00 | RNS |
Directorate Change | 03-Aug-2022 | 14:55 | RNS |
PTSD trials with top 10 pharma company & US DoD | 28-Jul-2022 | 07:00 | RNS |
Grant of Options | 26-Jul-2022 | 07:00 | RNS |
Second Price Monitoring Extn | 22-Jul-2022 | 11:05 | RNS |
Price Monitoring Extension | 22-Jul-2022 | 11:00 | RNS |
Director/PDMR Share Purchases | 22-Jul-2022 | 07:00 | RNS |
Trading Update and Notice of Results | 21-Jul-2022 | 07:00 | RNS |
Second Price Monitoring Extn | 14-Jul-2022 | 11:06 | RNS |
Price Monitoring Extension | 14-Jul-2022 | 11:00 | RNS |
Holding(s) in Company | 30-Jun-2022 | 17:43 | RNS |
Result of AGM | 08-Jun-2022 | 15:14 | RNS |
Posting of Annual Report & Notice of AGM | 16-May-2022 | 16:35 | RNS |
Results for the year ended 31 December 2021 | 12-Apr-2022 | 07:00 | RNS |
Senior Management Appointments | 06-Apr-2022 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 45.33p |
Change Today | 0.33p |
% Change | 0.74 % |
52 Week High | 104.00 |
52 Week Low | 44.07 |
Volume | 3,911 |
Shares Issued | 35.15m |
Market Cap | £15.93m |
RiskGrade | 282 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
08:36 | 3,488 @ 44.07p |
08:03 | 423 @ 44.99p |
Chair | Steven John Powell |
CEO | Matthew Stork |
CFO | Stephen Symonds |
You are here: research